Key facts
- mybacs’s last known valuation is $22.1M (Oct 2023).
- It has raised $9.4M; the latest was Later Stage VC ($1.4M) in Jan 2025.
- Notable investors include Global Founders Capital, Joyance Partners, Generations Fund, Management Capital Holding, SevenVentures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for mybacs
- ·The full record, as it builds
Funding rounds
No funding rounds for mybacs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About mybacs
Operator of a synbiotic dietary supplements brand, intended to offer synbiotic supplements. The company's supplements are specialized in the human microbiome, which are personalized and gluten-free, lactose-free and free of any chemical side effects, enabling customers to improve digestion and prevent diarrhea.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Munich, Germany
- Founded
- 2018
- Employees
- 27
- Website
- mybacs.com/
- Ownership
- Privately Held (backing)
mybacs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in mybacs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on mybacs in its N-PORT filings yet. We sweep new filings monthly.